Skip to main content
BioCentury
As published for the week of Monday, July 27, 2015


  • Cover Story: Strategy: Rules of competition

    How companies can compete with gene therapies that provide a functional cure

    By Stephen Hansen, Associate Editor

    Competing in gene therapy is unlikely to follow the same rules as competing in other therapeutic categories where — even in Orphan diseases — a better product can steal market share. The reason is that if the first gene therapies to market deliver on the promise of a functional cure, there may not be any patients left to treat.

    Investors have poured at least $3 billion into 20 companies developing gene therapies for Orphan indications that have one or more competitors working on the same gene — including $1 billion to bluebird bio Inc. alone. Most of these companies have touted potential benefits of their products over more advanced competitors targeting the same genes.

    Full Article

Money Raised in 2015

Last week, the biotech industry raised $1,782 million, bringing to $62.4 billion the total raised year-to-date. In 2014, a total of $54.8 billion was raised, including $21.5 billion in debt, $11.1 billion in follow-ons, $4 billion in PIPEs and other equity, $9.1 billion in IPOs, and $9.1 billion in venture capital. Totals include overallotments and warrants, and are rounded to the nearest millions.

Subscribe Now
Free Trial

Management Updates

There were no items published for this section in the most recent issue. Click more >> to read previously published items.

Preclinical Results

There were no items published for this section in the most recent issue. Click more >> to read previously published items.